Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Other Non Operating Income (2016 - 2020)

Summit Therapeutics filings provide 7 years of Other Non Operating Income readings, the most recent being $416000.0 for Q3 2020.

  • Quarterly Other Non Operating Income rose 654.67% to $416000.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was -$4.5 million through Sep 2020, down 471.37% year-over-year, with the annual reading at -$536000.0 for FY2019, 119.27% down from the prior year.
  • Other Non Operating Income hit $416000.0 in Q3 2020 for Summit Therapeutics, up from -$3.4 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $1.6 million in Q1 2018 and bottomed at -$3.4 million in Q1 2020.
  • Average Other Non Operating Income over 5 years is -$142731.3, with a median of -$146000.0 recorded in 2016.
  • Peak annual rise in Other Non Operating Income hit 2100.0% in 2016, while the deepest fall reached 10598.61% in 2016.
  • Summit Therapeutics' Other Non Operating Income stood at -$165000.0 in 2016, then rose by 1.15% to -$163100.0 in 2017, then skyrocketed by 272.77% to $281788.5 in 2018, then crashed by 126.62% to -$75000.0 in 2019, then skyrocketed by 654.67% to $416000.0 in 2020.
  • Per Business Quant, the three most recent readings for SMMT's Other Non Operating Income are $416000.0 (Q3 2020), -$3.4 million (Q1 2020), and -$75000.0 (Q3 2019).